← signals
2026-07-07·OPENAI·hyperscaler internal chip
lowup

A Manifold Markets prediction market shows a 93.15% consensus that OpenAI will design and manufacture a custom AI chip...

A Manifold Markets prediction market shows a 93.15% consensus that OpenAI will design and manufacture a custom AI chip by 2030 (source).

window 90devidence 16confidence score 91

confidence score

Strong evidence: 1 independent source class support this read.

91
low confidence1 independent source classesmarketpasses publish gate

signal brief

A Manifold Markets prediction market shows a 93.15% consensus that OpenAI will design and manufacture a custom AI chip by 2030 (source). This high probability indicates market belief in OpenAI's move toward vertical integration in AI hardware, a significant shift for semiconductor supply dynamics. While no official announcement has been made, the prediction reflects growing speculation that OpenAI may follow other hyperscalers in developing in-house silicon to reduce reliance on external GPU suppliers. Other prediction markets on the platform show low probabilities for GPT-6 release by August 2026 (8.07%) and for OpenAI selling compute externally (10.83%), suggesting a focus on internal chip development rather than expanding cloud services. The market for sharing software to run on multi-chip providers also remains low (24.71%), implying limited near-term flexibility. If realized, OpenAI's custom chip could reshape competitive dynamics in AI infrastructure, potentially affecting GPU demand from NVIDIA and AMD.

What the sources said

  • Source 1: 'YES=93.15%' on question 'Will OpenAI design and manufacture a custom AI chip by 2030?'
  • Source 4: 'YES=8.07%' on question 'Will OpenAI release a model marketed as GPT-6 by August 31, 2026?'
  • Source 16: 'YES=10.83%' on question 'OpenAI sells/rents AI compute to external customers by end-2026?'
  • Source 2: 'YES=24.71%' on question about publicly sharing multi-chip software in 2026.

source data used

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.